Trial Size Available
Carrier-Free Available

| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol |
|---|---|---|
| Flow Cytometry (Flow) | 1-2ug/million cells | Flow Cytometry Protocol |
| Immunofluorescence (IF) | 1-3ug/ml |
Inhibitor of E2F-dependent transcription (PubMed:9501179, PubMed:9689056, PubMed:9704927). Binds DNA cooperatively with DP proteins through the E2 recognition site, 5′-TTTC[CG]CGC-3′ (PubMed:9501179). Has a preference for the 5′-TTTCCCGC-3′ E2F recognition site (PubMed:9501179). E2F6 lacks the transcriptional activation and pocket protein binding domains (PubMed:9501179, PubMed:9704927). Appears to regulate a subset of E2F-dependent genes whose products are required for entry into the cell cycle but not for normal cell cycle progression (PubMed:9501179, PubMed:9689056). Represses expression of some meiosis-specific genes, including SLC25A31/ANT4 (By similarity). May silence expression via the recruitment of a chromatin remodeling complex containing histone H3-K9 methyltransferase activity. Overexpression delays the exit of cells from the S-phase (PubMed:9501179).
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time